Next Article in Journal
Long-Term Antitumor CD8+ T Cell Immunity Induced by Endogenously Engineered Extracellular Vesicles
Previous Article in Journal
Alterations of the Platelet Proteome in Lung Cancer: Accelerated F13A1 and ER Processing as New Actors in Hypercoagulability
cancers-logo
Article Menu

Article Menu

Guidelines

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer

1
Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt
2
Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94158, USA
3
Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Giza 12613, Egypt
4
Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, Washington, DC 20007, USA
5
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
6
Breast Center, Clinique de Genolier, 1272 Genolier, Switzerland
7
Department of Hematology & Oncology, Mayo Clinic, Jacksonville, FL 32224, USA
8
Breast Health Global Initiative, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98195, USA
9
Department of Pathology, Clermont Auvergne University, INSERM U1240 “Molecular Imaging and Theranostic Strategies”, Center Jean Perrin, Montalembert, 63000 Clermont-Ferrand, France
10
Department of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto IOV IRCCS, 35128 Padova, Italy
11
Department of Internal Medicine, Division of Hematology Oncology, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon
12
Subang Jaya Medical Centre, Kuala Lumpur 47500, Malaysia
13
Hematology and Oncology Department, Saint Joseph University, Beirut 1104 2020, Lebanon
14
Iridium Kankernetwerk and Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk-Antwerp, Belgium
15
Clinical oncology Department, Menoufia University, Shebin Elkom 51132, Egypt
16
Department of Surgery, Surgical Oncology Division, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
17
Department of Breast Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
18
Institut Universitaire de Cancérologie AP-HP. Sorbonne Université, INSERM U938, 75013 Paris, France
19
Breast & Endocrine Surgery Unit, Marmara University School of Medicine, University Hospital, Istanbul 34722, Turkey
20
Federal State Budgetary Institution “NN Blokhin National Medical Research Center of Oncology” of the Ministry of Health of the Russian Federation, 127994 Moscow, Russia
21
Surgical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
22
Scientific Directorate, IRCCS European Institute of Oncology (IEO), and University of Milan, 20122 Milan, Italy
23
Al Hyatt Oncology Practice, Amman 11183, Jordan
24
Department of Clinical Oncology, Alexandria School of Medicine, Alexandria 21131, Egypt
25
Russian Association of Oncological Mammology, Department of Breast Tumours of Federal State Budgetary Institution “Petrov Research Institute of Oncology”, 197758 Saint Petersburg, Russia
26
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Adult Medical Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah 22384, Saudi Arabia
27
Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo 11566, Egypt
28
Vice President of Galala University, Galala University, Suez 435611, Egypt
29
Department of Pathology, Ain shams University, Cairo 11566, Egypt
30
Oncology Department, Alfaisal university, Alhabib Hospital, Riyad 11533, Saudi Arabia
31
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China
32
The School of Public Health, University of Adelaide, Adelaide 5005, Australia
33
Biomedical Genomics & Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, Abdel Malek Essaadi University, Tangier 90000, Morocco
*
Authors to whom correspondence should be addressed.
Academic Editor: Marija Balić
Cancers 2021, 13(9), 2262; https://doi.org/10.3390/cancers13092262
Received: 7 April 2021 / Revised: 1 May 2021 / Accepted: 5 May 2021 / Published: 8 May 2021
Despite the impressive progress in the treatment of triple-negative breast cancer (TNBC), oncologists still face several provocative clinical scenarios in daily practice where clear evidence-based recommendations are lacking, and expert opinion is of utmost importance. In an attempt to seek guidance for these controversial topics in TNBC management, a consensus recommendations session for TNBC was held during the 12th round of the Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020. This special session convened a multidisciplinary committee of 35 panellists who specialize in breast cancer care from 13 countries. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.
Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials. View Full-Text
Keywords: triple-negative breast cancer; consensus; immunotherapy; BRCA mutations; platinum triple-negative breast cancer; consensus; immunotherapy; BRCA mutations; platinum
Show Figures

Figure 1

MDPI and ACS Style

Elghazaly, H.; Rugo, H.S.; Azim, H.A.; Swain, S.M.; Arun, B.; Aapro, M.; Perez, E.A.; Anderson, B.O.; Penault-Llorca, F.; Conte, P.; El Saghir, N.S.; Yip, C.-H.; Ghosn, M.; Poortmans, P.; Shehata, M.A.; Giuliano, A.E.; Leung, J.W.T.; Guarneri, V.; Gligorov, J.; Gulluoglu, B.M.; Abdel Aziz, H.; Frolova, M.; Sabry, M.; Balch, C.M.; Orecchia, R.; El-Zawahry, H.M.; Al-Sukhun, S.; Abdel Karim, K.; Kandil, A.; Paltuev, R.M.; Foheidi, M.; El-Shinawi, M.; ElMahdy, M.; Abulkhair, O.; Yang, W.; Aref, A.T.; Bakkach, J.; Bahie Eldin, N.; Elghazawy, H. Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers 2021, 13, 2262. https://doi.org/10.3390/cancers13092262

AMA Style

Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip C-H, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H. Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers. 2021; 13(9):2262. https://doi.org/10.3390/cancers13092262

Chicago/Turabian Style

Elghazaly, Hesham; Rugo, Hope S.; Azim, Hamdy A.; Swain, Sandra M.; Arun, Banu; Aapro, Matti; Perez, Edith A.; Anderson, Benjamin O.; Penault-Llorca, Frederique; Conte, Pierfranco; El Saghir, Nagi S.; Yip, Cheng-Har; Ghosn, Marwan; Poortmans, Philip; Shehata, Mohamed A.; Giuliano, Armando E.; Leung, Jessica W.T.; Guarneri, Valentina; Gligorov, Joseph; Gulluoglu, Bahadir M.; Abdel Aziz, Hany; Frolova, Mona; Sabry, Mohamed; Balch, Charles M.; Orecchia, Roberto; El-Zawahry, Heba M.; Al-Sukhun, Sana; Abdel Karim, Khaled; Kandil, Alaa; Paltuev, Ruslan M.; Foheidi, Meteb; El-Shinawi, Mohamed; ElMahdy, Manal; Abulkhair, Omalkhair; Yang, Wentao; Aref, Adel T.; Bakkach, Joaira; Bahie Eldin, Nermean; Elghazawy, Hagar. 2021. "Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer" Cancers 13, no. 9: 2262. https://doi.org/10.3390/cancers13092262

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop